Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | ATF1 | P18846 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4372326 | 0.98 | CES2 (0.64) | CES2GAARXRARXRBRXRG | |
| Hydrochloric Acid SCHEMBL4027010 | 0.98 | CES2 (0.64) | CES2GAARXRARXRBRXRG | |
| Trifluoroacetic Acid SCHEMBL5572977 | 0.92 | CES2 (0.57) | CES2GAARXRARXRBRXRG | |
| SCHEMBL17048542 | 0.92 | CES2 (0.57) | CES2GAARXRARXRBRXRG | |
| SCHEMBL23224106 | 0.90 | CES2 (0.55) | CES2GAARXRARXRBRXRG | |
| SCHEMBL16380759 | 0.90 | CES2 (0.55) | CES2GAARXRARXRBRXRG | |
| SCHEMBL4472344 | 0.87 | CES2 (0.52) | CES2GAARXRARXRBRXRG | |
| SCHEMBL2452507 | 0.87 | CES2 (0.52) | CES2GAARXRARXRBRXRG | |
| SCHEMBL30437904 | 0.87 | CES2 (0.52) | CES2GAARXRARXRBRXRG | |
| SCHEMBL628456 | 0.87 | CES2 (0.52) | CES2GAARXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119499350-A | Tumor targeting compound and preparation and application thereof | 南京大学 | 2025-02-25 | — | — | CN | claimed |
| CN-119264075-A | Lysosome oriented nanofiber monomer and preparation and application thereof | 南京大学 | 2025-01-07 | — | — | CN | claimed |
| CN-118667494-A | Preparation method of special composite binder for silicon-carbon negative electrode | 深圳光风新能源科技创新中心有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-117551417-A | Preparation method of special composite binder for silicon-carbon negative electrode | 深圳光风新能源科技创新中心有限公司 | 2024-02-13 | — | — | CN | claimed |
| US-11894429-B2 | Amorphous metal oxide semiconductor layer and semiconductor device | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2024-02-06 | — | — | US | claimed |
| CN-117511549-A | Selective BOE etching solution | 多氟多新材料股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-20220328635-A1 | AMORPHOUS METAL OXIDE SEMICONDUCTOR LAYER AND SEMICONDUCTOR DEVICE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2022-10-13 | — | — | US | claimed |
| US-20200350413-A1 | AMORPHOUS METAL OXIDE SEMICONDUCTOR LAYER AND SEMICONDUCTOR DEVICE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2020-11-05 | — | — | US | claimed |
| US-10756190-B2 | Precursor composition for forming amorphous metal oxide semiconductor layer, amorphous metal oxide semiconductor layer, method for producing same, and semiconductor device | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2020-08-25 | — | — | US | claimed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-1377579-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Aventis Pharmaceuticals Inc. (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | claimed |
| WO-2003059899-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTISUB LLC | 2003-04-10 | — | — | US | claimed |
| CN-1391564-A | Chemical compounds | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | CN | claimed |
| WO-2002042303-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | claimed |
| EP-1019367-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-07-19 | — | — | EP | claimed |
| WO-1999007672-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-02-18 | — | — | WO | claimed |
| WO-1998017636-A1 | PHENYLALANINOL DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-04-30 | — | — | WO | claimed |
| WO-1993014062-A1 | ANTHELMINTIC β-KETOAMIDES | THE UPJOHN COMPANY (US) | 1993-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | NR3C1, NR3C2, MC2R | CES2 4013/4885GAA 3090/4885RXRA 680/4885 |
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | BAD, BAX, MCL1 | CES2 1892/4885GAA 784/4885RXRA 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.